Inozyme Pharma, Inc.·4

Mar 17, 4:25 PM ET

Winton Matthew 4

4 · Inozyme Pharma, Inc. · Filed Mar 17, 2025

Insider Transaction Report

Form 4
Period: 2025-03-11
Transactions
  • Award

    Restricted Stock Units

    2025-03-11+41,50041,500 total
    Common Stock (41,500 underlying)
  • Award

    Stock Option (right to buy)

    2025-03-11+145,000145,000 total
    Exercise: $1.06Exp: 2035-03-10Common Stock (145,000 underlying)
Footnotes (3)
  • [F1]The exercise price represents the closing price of the Issuer's common stock on March 11, 2025.
  • [F2]The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.
  • [F3]The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4